Positions

Selected Publications

Chapter

Year Title Altmetric
2015 Interaction of Chemotherapy and Radiation.  63-79.e4. 2015

Research Overview

  • Many cancer therapies attack cellular DNA to cause DNA damage. The DNA double strand break (DSB) is the most critical form of DNA damage that induces both normal and cancer cell death if left unrepaired. My research interests involve the targeting of DNA repair pathways to enhance the therapeutic ratio. We aim to discover novel strategies to augment DNA repair pathways to specifically protect normal cells from DNA damage while reducing DNA repair capacity to convert cancer cells to become more susceptible to DNA damaging agents. Ultimately, we hope to translate our work into the clinic to deferentially treat cancer while sparing normal cells to maintain quality of life.

    Keywords - nanostring, profiling, DNA damage, DNA repair, EGFR, cancer, PARP, apoptosis, brain, protection, GSK3
  • Principal Investigator On

  • Biomarkers for Detection of Renal Cell Carcinoma  awarded by American Cancer Society, Inc.
  • Can Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling Induce Synthetic Lethality with Poly (ADP-Ribose) Polymerase Inhibition (PARPi) by Generating a DNA Repair Defect?  awarded by Kimmel (Sidney) Foundation for Cancer Research
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Experimental Therapeutics Program  awarded by National Cancer Institute/NIH/DHHS
  • DNA Repair Independent Mechanisms of HER2+ Tumor Sensitivity to PARP Inhibition  awarded by Komen (Susan G.) Breast Cancer Foundation
  • Elevated NF-kB Signaling in Breast Cancers of African American Women  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • Exploiting TNBC Vulnerabilities Via Rationally Combined Therapies  awarded by American Association for Cancer Research
  • HER2 Overexpression Confers Susceptibility to PARP Inhibition  awarded by American Association for Cancer Research
  • Mechanisms by Which GSK3B Inhibition Enhances Nonhomologous End-Joining Repair  awarded by GABRIELLE'S ANGEL FOUNDATION
  • Mutant p53 Reactivation as a Targeted Approach for Radio-Sensitization of Malignancies Harboring Disruptive Mutations in TP53 Gene.  awarded by Radiological Society of North America
  • Phase IB Trial of Radium-223 and Niraparib in Patients with Castrate Resistant Prostate Cancer  awarded by THOMAS JEFFERSON UNIVERSITY - NEW
  • Private Grant  awarded by ABBOTT LABORATORIES
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by PROSTATE CANCER CLINICAL TRIALS CONSORTIUM, LLC
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by CLOVIS ONCOLOGY
  • Private Grant  awarded by ASTRAZENECA AB
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ARCUS BIOSCIENCES INC
  • Private Grant  awarded by PUMA BIOTECHNOLOGY, INC.
  • Private Grant  awarded by ELI LILLY AND COMPANY
  • Private Grant  awarded by ELEVATION ONCOLOGY INC.
  • Private Grant  awarded by STRATA ONCOLOGY
  • Private Grant  awarded by STRATA ONCOLOGY
  • Targeting Homology-Directed Recombinational Repair (HDR) of Chromosomal Breaks to Sensitize Prostate Cancer Cells to Poly (ADP-Ribose) Polymerase (PARP) Inhibition  awarded by DOD - Department of Defense
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology
  • UAB 1846: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes  awarded by Johns Hopkins University
  • Investigator On

  • A New Paradigm: Using PARP Inhibitors to Treat HER2+ Breast Cancer  awarded by Komen (Susan G.) Breast Cancer Foundation
  • A Prospective Comparative Study of Outcomes with Proton and Photon Radiation in Prostate Cancer  awarded by University of Florida^
  • A Targeted Mitochondrial Luminoptogenetic Gene Therapy to Treat Triple Negative Breast Cancer  awarded by DOD - Department of Defense
  • American Society of Clinical Oncology survey on COVID19 in Oncology Registry  awarded by American Society of Clinical Oncology
  • Clinical and Molecular Biomarkers of Endpoints in Pediatric Renal Transplantation  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Create Access to Targeted Cancer Therapy for Underserved Populations (CATCH-UP)  awarded by National Cancer Institute/NIH/DHHS
  • Comprehensive Cancer Center Core Support Grant - Integrating Basic Science And Community Outreach And Engagement To Bridge The Transdisciplinary Cancer Research Continuum  awarded by National Cancer Institute/NIH/DHHS
  • Deciphering How Esco2 Loss Acts as a Penetrance Modifier  awarded by National Cancer Institute/NIH/DHHS
  • Developing Novel Combination Therapies for Pancreatic Cancer  awarded by National Cancer Institute/NIH/DHHS
  • Developing Therapy for the Treatment of Cholangiocarcinoma  awarded by National Cancer Institute/NIH/DHHS
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group
  • Integrating Genomic Risk Assessment for Chronic Disease Management in a Diverse Population  awarded by National Human Genome Research Institute/NIH/DHHS
  • Mechanism of Ultraviolet Radiation Induced Immune Tolerance  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • ONE SHOT - Single Shot Radiotherapy for Localized Prostate Cancer - A Multicenter, Single Arm, Phase I/II Trial  awarded by GENEVA UNIVERSITY HOSPITAL
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by Novartis Pharma AG
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by SUCAMPO PHARMACEUTICALS
  • Private Grant  awarded by VARIAN MEDICAL SYSTEMS, INC.
  • Private Grant  awarded by IMAGINAB^
  • Private Grant  awarded by MERCK SHARP & DOHME CORP
  • Quantitative Imaging To Personalize Therapy in Her2 Breast Cancer  awarded by American Cancer Society, Inc.
  • RAD 2001 (2012-0825): Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER)
  • RTOG Foundation Master Service Agreement for Participation in Foundation Research: RTOG 3501 Tryhard: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb) for Non-HPV Locally Advanced Head and Neck Cancer with Concurrent Chemoradiation  awarded by American College of Radiology
  • SWOG Purchase Services Agreement  awarded by Oregon Health & Science University
  • TBCRC 050 UAB 17112-A Phase 1b/2 Study of the PARP Inhibitor Niraparib in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer  awarded by Johns Hopkins University
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Using the Genomic Profile of High Intermediate Risk Endometrial Cancer Patients to Differentiate Patients at High Risk of Recurrence from the Majority with Low Risk of Recurrence  awarded by FOUNDATION FOR GYNECOLOGIC ONCOLOGY
  • Education And Training

  • Mount Sinai Hospital, Internship
  • Vanderbilt University Medical Center, Residency
  • Doctor of Medicine, University of Miami 2005
  • Doctor of Philosophy in Molecular Pharmacology, University of Miami 2005
  • Full Name

  • Eddy Yang